Matthew Phipps's questions to Genmab A/S (GMAB) leadership • Q1 2025
Question
Matthew Phipps of William Blair asked if Genmab is considering using the FDA's Project FrontRunner pathway for other ongoing or planned Phase 3 studies, such as the frontline follicular lymphoma trial.
Answer
CMO Tahamtan Ahmadi responded that while the company will always explore innovative regulatory pathways to accelerate patient access, such approaches are contingent on having 'compelling data.' He indicated that this was the case for the second-line follicular lymphoma submission but did not commit to using the pathway for other specific trials, stating it depends on the strength of future data.